Agenus, Inc. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 73

Agenus, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Agenus, Inc. - Product Pipeline Review - 2012” provides data on the Agenus, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Agenus, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Agenus, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Agenus, Inc. - Brief Agenus, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Agenus, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Agenus, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Agenus, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Agenus, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Agenus, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Agenus, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Agenus, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Agenus, Inc. and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of Agenus, Inc.; Agenus, Inc. - Key Therapeutics; Agenus, Inc. - Pipeline Overview and Promising Molecules; Agenus, Inc. - News; Agenus, Inc. - Latest Updates; Agenus, Inc. - Pipeline; Agenus, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Agenus, Inc. Snapshot
Agenus, Inc. Overview
Key Information
Key Facts
Agenus, Inc. – Research and Development Overview
Key Therapeutic Areas
Agenus, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Agenus, Inc. – Pipeline Products Glance
Agenus, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Agenus, Inc. – Drug Profiles
HerpV
Product Description
Mechanism of Action
R&D Progress
Nystatin
Product Description
Mechanism of Action
R&D Progress
Prophage
Product Description
Mechanism of Action
R&D Progress
Agenus, Inc. – Pipeline Analysis
Agenus, Inc. – Pipeline Products by Therapeutic Class
Agenus, Inc. – Pipeline Products By Target
Agenus, Inc. – Pipeline Products by Route of Administration
Agenus, Inc. – Pipeline Products By Mechanism of Action
Agenus, Inc. – Recent Pipeline Updates
Agenus, Inc. - Dormant Projects
Agenus, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Aroplatin
ATRA-IV
AU-801
HSPPC-70
Zintevir
Agenus, Inc. – Company Statement
Agenus, Inc. – Locations And Subsidiaries
Head Office
Agenus, Inc., Recent Developments
Agenus, Inc.- Press Release
Apr 17, 2012: Agenus Presents New Phase II Data From Brain Cancer Study Of Prophage Vaccine At Plenary Session Of AANS
Apr 17, 2012: NCI Group Selects HSPPC-96 Vaccine For Randomized Large-Scale Study With Bevacizumab For Recurrent Glioblastoma
Apr 02, 2012: Agenus's Phase II Study Of Brain Cancer Vaccine To Be Presented At 80th AANS Annual Scientific Meeting
Aug 12, 2009: Antigenics Begins Enrollment Of Patients In Its Phase II Trial Of Oncophage Cancer Vaccine In Newly Diagnosed Glioma
Jun 01, 2009: Antigenics Presents Positive Oncophage Interim Survival Data At ASCO
Mar 12, 2009: Antigenics Receives European Orphan Drug Designation For Oncophage Cancer Vaccine In Brain Cancer
Financial Deals Landscape
Agenus, Inc., Deals Summary
Agenus, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Agenus Enters Into Research Agreement With Memorial Sloan-Kettering Cancer Center
Licensing Agreements
Agenus Amends Licensing Agreement With GlaxoSmithKline For QS-21 Stimulon
Agenus Enters Into Licensing And Development Agreement With NewVac For Oncophage
Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For QS-21 Stimulon
Antigenics Enters Into Licensing Agreement With Johnson & Johnson
GlaxoSmithKline Expands Licensing Agreement With Antigenics
Antigenics Enters Into Licensing Agreement With Pharmexa
Equity Offering
Agenus Files Registration Statement For Private Placement Of Up To 5 Million Shares
Agenus Completes Public Offering Of Common Stock For $7 Million
Antigenics Files Shelf Registration Statement For Private Placement
Antigenics Completes Public Offering Of $8.5 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $0.8 Million
Antigenics Completes Private Placement Of $21 Million
Antigenics Completes Private Placement Of $26 Million
Antigenics Completes Private Placement Of $5 Million
Antigenics Completes Public Offering Of $57 Million
Debt Offering
Antigenics Completes Private Placement Of 8% Senior Notes For $25 Million
Antigenics Completes Private Placement Of 5.25% Senior Notes For $50 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Agenus, Inc., Key Information
Agenus, Inc., Key Facts
Agenus, Inc. – Pipeline by Indication, 2012
Agenus, Inc. – Pipeline by Stage of Development, 2012
Agenus, Inc. – Monotherapy Products in Pipeline, 2012
Agenus, Inc. – Phase II, 2012
Agenus, Inc. – Phase I, 2012
Agenus, Inc. – Pipeline By Therapeutic Class, 2012
Agenus, Inc. - Pipeline By Target, 2012
Agenus, Inc. – Pipeline By Route of Administration, 2012
Agenus, Inc. – Pipeline Products By Mechanism of Action, 2012
Agenus, Inc. – Recent Pipeline Updates, 2012
Agenus, Inc. - Dormant Developmental Projects,2012
Agenus, Inc. - Discontinued Pipeline Products, 2012
Agenus, Inc., Deals Summary
Agenus Enters Into Research Agreement With Memorial Sloan-Kettering Cancer Center
Agenus Amends Licensing Agreement With GlaxoSmithKline For QS-21 Stimulon
Agenus Enters Into Licensing And Development Agreement With NewVac For Oncophage
Agenus Enters Into Licensing Agreement With Integrated BioTherapeutics For QS-21 Stimulon
Antigenics Enters Into Licensing Agreement With Johnson & Johnson
GlaxoSmithKline Expands Licensing Agreement With Antigenics
Antigenics Enters Into Licensing Agreement With Pharmexa
Agenus Files Registration Statement For Private Placement Of Up To 5 Million Shares
Agenus Completes Public Offering Of Common Stock For $7 Million
Antigenics Files Shelf Registration Statement For Private Placement
Antigenics Completes Public Offering Of $8.5 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $0.8 Million
Antigenics Completes Private Placement Of $21 Million
Antigenics Completes Private Placement Of $26 Million
Antigenics Completes Private Placement Of $5 Million
Antigenics Completes Public Offering Of $57 Million
Antigenics Completes Private Placement Of 8% Senior Notes For $25 Million
Antigenics Completes Private Placement Of 5.25% Senior Notes For $50 Million

List of Figures
Agenus, Inc. – Pipeline by Indication, 2012
Agenus, Inc. – Pipeline by Stage of Development, 2012
Agenus, Inc. – Monotherapy Products in Pipeline, 2012
Agenus, Inc. – Pipeline By Therapeutic Class, 2012
Agenus, Inc. - Pipeline By Target, 2012
Agenus, Inc. – Pipeline By Route of Administration, 2012
Agenus, Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Analysis of Google Inc
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Ixia - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Dell Inc.
• SunGard - Profile - US
• CIBER Inc